P370: Concomitant azathioprine prevents new-onset arthralgia after initiation of vedolizumab: A retrospective cohort studyECCO'21 VirtualYear: 2021
Authors: Kokkotis, G.(1);Zampeli, E.(2);Tzouvala, M.(3);Giotis, I.(3);Orfanos, P.(4);Benetou, V.(4);Stoupaki, M.(2);Gizis, M.(1);Kioulos, N.(1);Kitsou, V.(1);Leontidis, N.(3);Leonidakis, G.(2);Chatzinikolaou, M.L.(1);Perlepe, N.(1);Koutsounas, I.(1);Lagiou, P.(4);Michopoulos, S.(2);Bamias, G.(1);
(1)3rd Department of Internal Medicine- National and Kapodistrian University of Athens- Sotiria Hospital, GI Unit, Athens, Greece;(2)Alexandra General Hospital, Gastroenterology Department, Athens, Greece;(3)General Hospital Nikaias-Piraeus Agios Panteleimon- General Hospital Dytikis Attikis Agia Varvara, GI Department, Piraeus, Greece;(4)Epidemiology and Medical Statistics- School of Medicine- National and Kapodistrian University of Athens, Department of Hygiene, Athens, Greece
P371: Using digital monitoring during the COVID pandemic to streamline outpatient appointmentsECCO'21 VirtualYear: 2021
Authors: Walsh, A.J.(1);Matini, L.(1);Wilson, J.(1);Lyden, S.(1);Al-Hillawi, L.(1);Kantschuster, R.(1);Kormilitzin, A.(2);Smith, T.(1);Slater, J.(1);Payton, S.(1);White, L.(1);Woodley, H.(1);Brain, O.(1);Palmer, R.(1);Ambrose, T.(1);Satsangi, J.(1);Travis, S.P.L.(1);
(1)Oxford University Hospitals NHS Foundation Trust, Translational Gastroenterology Unit, Oxford, United Kingdom;(2)University of Oxford, Mathematical Institute, Oxford, United Kingdom
P372: Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCUECCO'21 VirtualYear: 2021
Authors: Mesonero Gismero, F.(1);Zabana, Y.(2);Fernández-Clotet, A.(3);Leo, E.(4);Caballol, B.(3);Núñez, A.(4);García, M.J.(5);Bertoletti, F.(6);Mínguez, A.(7);Suris, G.(8);Casis, B.(9);Ferreiro-Iglesias, R.(10);Calafat, M.(11);Jiménez, I.(12);Miranda-Bautista, J.(13);Lamuela, L.J.(14);Fajardo, I.(15);Torrealba, L.(16);Nájera, R.(17);Sáiz, R.M.(18);González, I.(19);Vicuña, M.(20);García-Morales, N.(21);Gutiérrez, A.(22);López-García, A.(23);Benítez, J.M.(24);Rubín de Célix, C.(25);Tejido, C.(26);Brunet, E.(27);Hernández, A.(28);Suárez, C.(29);Piqueras, M.(30);Castaño, A.(31);Ramos, L.(32);Sobrino, A.(33);Rodríguez-Grau, M.C.(34);Elosua, A.(35);Montoro, M.(36);López-Sanromán, A.(1);Barreiro-de Acosta, M.(10);
(1)Hospital Universitario Ramón y Cajal, Department of Gastroenterology, Madrid, Spain;(2)Hospital Universitari Mutua Terrassa- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology, Barcelona, Spain;(3)Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain;(5)Hospital Universitario Marqués de Valdecilla- IDIVAL., Gastroenterology, Santander, Spain;(6)Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(7)Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain;(8)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(9)Hospital Universitario 12 de Octubre, Gastroenterology, Madrid, Spain;(10)Hospital Clínico Universitario Santiago, Gastroenterology, Santiago de Compostela, Spain;(11)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(12)Hospital Universitario Galdakao, Gastroenterology, Bilbao, Spain;(13)Hospital Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(15)Hospital Universitari Mutua Terrassa, Gastroenterology, Barcelona, Spain;(16)Hospital Universitari Doctor Josep Trueta, Gastroenterology, Girona, Spain;(17)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(18)Hospital Universitario Burgos, Gastroenterology, Burgos, Spain;(19)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain;(20)Complejo Hospitalario Navarra, Gastroenterology, Navarra, Spain;(21)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(22)Hospital General Universitario Alicante- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL., Gastroenterology, Alicante, Spain;(23)Hospital del Mar, Gastroenterology, Barcelona, Spain;(24)Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain;(25)Hospital Universitario La Princesa- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Instituto de Investigación Sanitaria Princesa IIS-IP., Gastroenterology, Madrid, Spain;(26)Complejo Hospitalario Universitario Ourense, Gastroenterology, Ourense, Spain;(27)Hospital Universitari Parc Taulí, Gastroenterology, Sabadell, Spain;(28)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Tenerife, Spain;(29)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(30)Consorci Sanitari Terrassa, Gastroenterology, Barcelona, Spain;(31)Hospital Universitario Central Asturias, Gastroenterology, Oviedo, Spain;(32)Hospital Universitario de Canarias, Gastroenterology, Tenerife, Spain;(33)Hospital General Universitario Ciudad Real, Gastroenterology, Ciudad Real, Spain;(34)Hospital Universitario del Henares, Gastroenterology, Coslada, Spain;(35)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(36)Hospital General Universitario San Jorge, Gastroenterology, Huesca, Spain; On behalf of the Young Group of GETECCU. RESERVO Study Group: Rodríguez Lago I Baston I Baltar R Huguet JM Hermida B Caballero-Mateos A Sánchez-Guillén L Bouhmidi A Pajares R
P373: Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysisECCO'21 VirtualYear: 2021
Authors: Rodrigues, I.(1);Damião, F.(1);Serrazina, J.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Baldaia, C.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário de Lisboa Norte - Hospital de Santa Maria, Gastroenterology, Lisbon, Portugal
P374: Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s disease.ECCO'21 VirtualYear: 2021
Authors: Savelkoul, E.(1);Maas, M.(1);Bourgonje, A.(2);Crouwel, F.(3);Russel, M.(4);Römkens, T.(5);De Boer, N.(3);Dijkstra, G.(2);Hoentjen, F.(1);
(1)Radboud University Medical Centre- Nijmegen- The Netherlands., Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)University Medical Centre Groningen- Groningen- The Netherlands., Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(3)Amsterdam University Medical Centre- VU University- AGEM Research Institute- Amsterdam- the Netherlands., Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Medisch Spectrum Twente- Enschede- The Netherlands., Department of Gastroenterology and Hepatology, Enschede, The Netherlands;(5)Jeroen Bosch Ziekenhuis- 's-Hertogenbosch- The Netherlands., Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands
P375: A simulation study to evaluate the performance of a multiple imputation method to address missing data in an analysis of clinical effectiveness using the ImproveCareNow Registry of pediatric patients with Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Zhang, N.(1,2);Liu, C.(1);King, E.(1,2);Chen, S.(1);Olano, K.(1);Steiner, S.(3);Colletti, R.(4);Saeed, S.(5);Strauss, R.(6);Volger, S.(6);Lo, K.H.(6);Wang, Y.(6);
(1)Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, Cincinnati, United States;(2)University of Cincinnati College of Medicine, Division of Biostatistics and Epidemiology, Cincinnati, United States;(3)Riley Hospital for Children/Indiana University School of Medicine, Pediatric Gastroenterology, Indianopolis, United States;(4)University of Vermont Children’s Hospital, Pediatrics, Burlington, United States;(5)Dayton Children’s Hospital/Wright State University, Pediatrics, Dayton, United States;(6)Janssen Research and Development- LLC, Immunology, Spring House, United States
P376: Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platformECCO'21 VirtualYear: 2021
Authors: Oddsson, S.(1);Gunnarsdottir, T.(1);Johannsdottir, L.(2);Amundadottir, M.(3);Frimannsdottir, A.(3);Ylanne, K.(4);Molander, P.(5);Islind, A.(2);Oskarsdottir, M.(2);Thorgeirsson, T.(1);
(1)Sidekick Health, Medical and Research Department, Kopavogur, Iceland;(2)Reykjavik University, Department of Computer Science, Reykjavik, Iceland;(3)Sidekick Health, Data Science Department, Kopavogur, Iceland;(4)Sidekick Health, Customer Success Department, Kopavogur, Iceland;(5)Helsinki University Hospital- Helsinki University, Abdominal Center- Gastroenterology, Helsinki, Finland
P377: Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database studyECCO'21 VirtualYear: 2021
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
(1)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(2)Ingress Health, HWM GmbH, Wismar, Germany;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Galapagos, Nv, Mechelen, Belgium
P378: Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trialECCO'21 VirtualYear: 2021
Authors: Gatti, S.(1);Cianfruglia, L.(2);Galeazzi, T.(1);Palpacelli, A.(1);Quattrini, S.(1);Quatraccioni, C.(3);Catassi, G.(1);Monachesi, C.(1);Di Sario, A.(3);Armeni, T.(2);Catassi, C.(1);
(1)Polytechnic University of Marche, Department of Pediatrics, Ancona, Italy;(2)Polytechnic University of Marche, Department of Clinical Sciences, Ancona, Italy;(3)Polytechnic University of Marche, Department of Gastroenterology, Ancona, Italy
P379: Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.ECCO'21 VirtualYear: 2021
Authors: Hilley, P.(1);Li Wai Suen, C.(1,2);Srinivasan, A.(1,2);Choy, M.C.(1,2);De Cruz, P.(1,2);
(1)AUSTIN HEALTH, Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine- Austin Academic centre, melbourne, Australia
P380: Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologicsECCO'21 VirtualYear: 2021
Authors: Temido, M.J.(1);Portela, F.(1);Lopes, S.(1);Mendes, S.(1);Ferreira, M.(1);Ferreira, M.(1);Figueiredo, P.(1);
(1)Centro Hospitalar e Universitário de Coimbra, Gastroenterology, Coimbra, Portugal
P381: Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Risager Christensen, K.(1);Steenholdt, C.(1);Buhl, S.(1);Skougaard, M.(2);Brynskov, J.(1);Ainsworth, M.A.(3);Schjødt Jørgensen, T.(2);Kristensen, L.E.(2);
(1)Gentofte and Herlev Hospital, Gastroenterology, Herlev, Denmark;(2)The Parker Institute- Copenhagen University Hospital, Rheumatology, Copenhagen, Denmark;(3)Odense University Hospital, Gastroenterology, Odense, Denmark
P382: High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel diseaseECCO'21 VirtualYear: 2021
Authors: Zvuloni, M.(1);Matar, M.(2);Levi, R.(3);Shamir, R.(1,2);Assa, A.(2,4);
(1)The Sackler Faculty of Medicine- Tel Aviv University- Israel, Medicine department, Tel Aviv, Israel;(2)Schneider Children's Hospital, The institute of Gastroenterology- Nutrition and Liver diseases, Petach-Tikva, Israel;(3)Schneider Children's Hospital, Pediatric department A, Petach-Tikva, Israel;(4)The Ben-Gurion University of the Negev-- Israel, Medicine department, Beer Sheva, Israel
P383: Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION studyECCO'21 VirtualYear: 2021
Authors: Peyrin-Biroulet , L.(1);Loftus Jr , E.V.(2);Hibi , T.(3);Birchwood , C.(4);Yun , C.(4);Zhao , S.(4);Liu , X.(4);Rogler , G.(5);Danese , S.(6);Colombel , J.F.(7);Feagan , B.(8);
(1)University Hospital of Nancy-University of Lorraine, Department of Gastroenterology and Inserm U954, Vandoeuvre-Lès-Nancy, France;(2)Mayo Clinic, Department of Internal Medicine-Department of Gastroenterology and Hepatology, Rochester, United States;(3)Kitasato Institute Hospital-Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(4)Gilead Sciences, Inc., Foster City, United States;(5)University Hospital of Zurich-University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland;(6)Humanitas Clinical and Research Center-IRCCS and Humanitas University, Department of Gastroenterology, Milan, Italy;(7)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology-Department of Medicine, New York City, United States;(8)Western University, Department of Medicine-Division of Gastroenterology, London, Canada
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdownECCO'21 VirtualYear: 2021
Authors: Paupard, T.(1);richez, C.(2);verlynde, J.(1);zaharia, O.(1);quartier, G.(1);hudziak, H.(1);delhoustal, L.(1);
(1)Centre Hospitalier, Service d'Hépato-Gastroentérologie, Dunkerque, France;(2)Centre Hospitalier, Service d'Addictologie, Dunkerque, France
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumabECCO'21 VirtualYear: 2021
Authors: Mardare, R.(1);Burgess, N.(1);Studart, D.(1);Deb, P.(1);Gasparetto, M.(1);Croft, N.(1);Naik, S.(1);Kadir, A.(1);
(1)Royal London Hospital, Paediatric Gastroenterology, London, United Kingdom
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemicECCO'21 VirtualYear: 2021
Authors: Lin, S.(1,2);Bewshea, C.(2);Chanchlani, N.(2);Chee, D.(1,2);Pollok, R.C.(3,4);Kennedy, N.A.(1,2);Ahmad, T.(1,2);Goodhand, J.R.(1,2);
(1)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)St George's University Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(4)St George's- University of London, Institute for Infection & Immunity, London, United Kingdom
P388: Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Mishkin, D.(1);Marano, C.(2);Simi, A.(2);Lynch, J.(2);Noonan, L.(2);Zhang, H.(2);Sands, B.E.(3);Reinisch, W.(4);
(1)Atrius Health, Gastroenterology, Boston, United States;(2)Janssen Research & Development- LLC, Immunology, Spring House, United States;(3)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Medical University of Vienna, Gastroenterology, Vienna, Austria; UNIFI